Skip to main content
. Author manuscript; available in PMC: 2014 Nov 5.
Published in final edited form as: Cancer Res. 2009 Apr 21;69(9):3910–3917. doi: 10.1158/0008-5472.CAN-08-0034

Figure 4.

Figure 4

Effect of APcK110 on the progression through the cell cycle and survival of OCI/AML3 cells. A) Cell cycle analysis using propdium iodide staining. OCI/AML3 cells were incubated for 2 hours with APcK110 at 500 nM. An increase in the sub-G0 fraction of cells at 2 hours to 27% from 10% (control) is demonstrated. B) Induction of caspase-dependent apoptosis. The Fig. shows apoptosis in the absence of presence of the caspase inhibitor Z-VAD-FMK (Annexin V assay). Concurrent incubation of OCI/AML3 cells with Z-VAD-FMK and APcK110 decreases apoptotic cell fraction from 73% to 26% (baseline activity 21%). C) Induction of apoptosis by activation of caspase 3 and cleavage of PARP. Western immunoblot analysis demonstrates concentration-dependent increase in caspase 3 with concurrent increase in levels of cleaved PARP.